Fredun Pharmaceuticals board approves 2:1 bonus issue
Fredun Pharmaceuticals' board has approved a 2:1 bonus issue and a final dividend of ₹0.70 per share for the fiscal year 2026. This decision follows the company's strong financial performance, with a 56% rise in net profit to ₹11 crore for the March 2026 quarter and a 59.59% increase in standalone net profit to ₹33.21 crore for the full FY26. The record date for the bonus issue will be announced later.
May 26 2026 17:44:23
Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Fredun Pharmaceuticals announced a 2:1 bonus issue of equity shares. The proposal entails issuing 2 new shares of ₹10 each for every 1 existing share, subject to shareholder approval and fixation of the record date.
May 25 2026 17:54:53
Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Fredun Pharmaceuticals reported robust FY26 performance, with revenue up 40% YoY to Rs.639.12 cr and net profit up 60% YoY to Rs.33.21 cr. The company also recommended a Rs.0.70 dividend per share and a 2:1 bonus issue, alongside a credit rating upgrade and facility expansion.
May 25 2026 17:50:29
Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Outcome Of Board Meeting Held On 25Th May, 2026
Fredun Pharmaceuticals board approved FY26 consolidated financial results, reporting revenue of ₹63,912.49 lakhs and net profit of ₹3,262.09 lakhs. The board recommended a final dividend of ₹0.70 per share and a 2:1 bonus share issue. Additionally, authorized share capital increased to ₹50 crores and new auditors were appointed for FY27.
May 25 2026 14:57:47
Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Fredun Pharmaceuticals has launched 'Daulcél', a premium wellness and longevity-focused platform. This initiative marks a strategic expansion into the rapidly growing preventive healthcare and healthy aging segments.
May 15 2026 22:30:58
Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Fredun Pharmaceuticals announced the launch of "HORMONE RANGE PRODUCTS," a premium brand focused on longevity and human performance therapeutics. This marks a strategic entry into a rapidly expanding, high-value healthcare segment.
May 15 2026 22:29:28
Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Fredun Pharma's Monitoring Agency Report for Q4 FY26 highlighted the agency's inability to confirm fund utilization from the preferential issue due to insufficient data provided by the company. The report also cited past instances of funds parked not in line with SEBI guidelines.
May 15 2026 22:27:52
Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Intimation for The Meeting To Be Held On Monday, 25 May, 2026.
Fredun Pharmaceuticals Board will convene on May 25, 2026, to discuss and approve the Q4 and full-year FY26 financial results. The agenda also includes recommendations for a final dividend and bonus shares, pending shareholder approval for the latter.
May 15 2026 13:09:14
Read More